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ABSTRACT 27 
Recent species-extrapolation approaches to predict the potential effects of pharmaceuticals present 28 
in the environment on wild fish are based on the assumption that pharmacokinetics and metabolism 29 
in humans and fish are comparable. To test this hypothesis, we exposed fathead minnows to the 30 
opiate pro-drug tramadol and examined uptake from the water into the blood and brain, and 31 
metabolism of the drug into its main metabolites. We found that plasma concentrations could be 32 
predicted reasonably accurately based on the lipophilicity of the drug, once the pH of the water was 33 
taken into account. The concentrations of the drug and its main metabolites were higher in the brain 34 
than in the plasma, and the observed brain/plasma concentration ratios were within the range of 35 
values reported in mammalian species. This fish species was able to metabolise the pro-drug 36 
tramadol into the highly active metabolite O-desmethyl tramadol and the inactive metabolite 37 
N-desmethyl tramadol in a similar manner to mammals. However, we found that concentration 38 
ratios of O-desmethyl tramadol to tramadol were lower in the fish than values in most humans 39 
administered the drug. Our pharmacokinetic data of tramadol in fish help bridge the gap between 40 
widely available mammalian pharmacological data and potential effects on aquatic organisms, and 41 
highlight the importance of understanding drug uptake and metabolism in fish to enable the full 42 
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INTRODUCTION 74 
  It is now well known that many different human pharmaceuticals are present in the rivers of 75 
essentially all countries. This is a consequence of them, and their metabolites, being excreted by 76 
people into the sewage system and not being completely removed by wastewater treatment.
1–4
 Many 77 
of these pharmaceuticals can be found in aquatic organisms such as fish.
5–10
 Due to the impracticality 78 
of testing all  human pharmaceuticals
11,12
 on fish and other aquatic organisms, which is a 79 
consequence of the large amount of time and resources that would be required to do so, as well as the 80 
ethical issues around conducting those ecotoxicity tests, the way forward has to be to reach a stage 81 
where it is possible to accurately predict the degree of threat these biologically-active molecules (and 82 
their metabolites) pose to aquatic organisms. Key steps in making those reliable predictions are 83 
understanding the occurrence and concentrations of the pharmaceutical in the aquatic environment 84 
and factors influencing the degree of its uptake, distribution, and metabolism in the organism 85 
(pharmacokinetics), as well as being able to predict the likely effects (pharmacodynamics). It is well 86 
known that the uptake of pharmaceuticals is mainly influenced by their physicochemical 87 
properties,
13–17
 and that the likelihood of effects is governed primarily by the presence or absence of 88 
the drug target.
18
 However, the steps between these two factors – namely internal distribution and 89 
metabolism in fish – are much less well understood. Understanding whether or not fish metabolise 90 
pharmaceuticals, and if so to what, is crucial to accurate predictions of risk, for a number of reasons. 91 
One is that many pharmaceuticals are detoxified (i.e., made inactive) by metabolism: the parent 92 
molecule is active, but the metabolites are not. Another is the opposite: some pharmaceuticals (the 93 
so-called pro-drugs) are inactive until they are metabolised, with the efficacy of the drug dependent 94 
on metabolism of the parent molecule into the pharmacologically active molecule(s). Finally, the 95 
possibility exist that fish, and other aquatic organisms, might metabolise pharmaceuticals differently 96 
to humans; if they did, different metabolites, which could have unique pharmacological activities, 97 
and hence lead to unanticipated effects, could be produced. Hence, if the read-across hypothesis
13,19
 98 
is to be maximally useful in aiding the prediction of the effects of pharmaceuticals on non-target 99 
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species such as fish, drug metabolism in these species needs to be understood. This study was 100 
designed to improve our knowledge of the uptake and metabolism of pharmaceuticals by fish 101 
through studying how they metabolise the pro-drug tramadol. 102 
  Tramadol, which is an opioid analgesic, is widely used to treat moderate to severe pain, acting as 103 
an agonist of µ-opioid receptors as well as being a serotonin and noradrenaline reuptake inhibitor. 104 
As tramadol is only partially removed in conventional wastewater treatment plants (WWTPs),
20–23
 105 
the compound has frequently been detected in surface waters around the world, at concentrations in 106 
the range of ng L
-1




 Some researchers have reported more than ten times 107 
higher concentrations of tramadol in South Wales (United Kingdom) than other regions ― the 108 
highest concentrations were 98 µg L
-1
 and 7.7 µg L
-1
 in wastewater effluents
20
 and surface waters
26
, 109 
respectively. Likewise, extremely high concentrations of tramadol ranging from 10 to 100 µg L
-1
 110 
were found in surface water from Cameroon.
27
 In widely used biodegradability tests from the 111 
OECD series, tramadol was characterized as a “not readily biodegradable” substance.
28
 A 112 




  The present study aimed at investigating the partitioning of tramadol between test water and fish 115 
blood, and between blood and brain in a teleost fish, the fathead minnow (Pimephales promelas), 116 
after 23−24 days of chronic waterborne exposure to tramadol. An additional aim was to investigate 117 
tramadol metabolism in fish by measuring the active metabolite O-desmethyl tramadol (T-M1) and 118 
the inactive metabolite N-desmethyl tramadol (T-M2), and to compare metabolism of tramadol in 119 
fish and mammalian species. In humans, metabolism of tramadol is mainly mediated by 120 
cytochrome P450 (CYP) 2D6, which transforms tramadol into the active metabolite T-M1, and by 121 
CYP2B6 and CYP3A4, which transforms tramadol into the inactive metabolite T-M2.
30
 122 
Considering the existing uncertainties around the evolutionary aspects and functional diversity of 123 
these enzymes (especially CYP2 subfamilies) in teleost fish,
31
 generating novel drug-metabolism 124 
data in fish can provide important information on the functional conservation of these metabolic 125 
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properties across species, and support species-extrapolation and predictive 126 
pharmacology/toxicology approaches. In order to facilitate data interpretation, we also quantified 127 
the metabolism of the antidepressant fluoxetine in the same species, and used it as a reference. 128 
Fluoxetine is metabolised to the equipotent active metabolite norfluoxetine through 129 
N-demethylation by CYP 2D6, 2C9, 2C19, and 3A4 in humans.
32
  130 
 131 
MATERIALS AND METHODS 132 
Chemicals. Tramadol hydrochloride was purchased from Sigma-Aldrich (Dorset, UK) with purity 133 
higher than 99% (product number 42965-5G-F, lot number BCBN4547V). Fluoxetine 134 
hydrochloride was purchased from Sigma-Aldrich (Dorset, UK) with purity higher than 99.9% 135 
(product number PHR1394, lot number LRAA1901). N, N-dimethylformamide (DMF) was 136 
obtained from Fisher Scientific (Loughborough, UK). Liquid chromatography–mass spectrometry 137 
grade methanol, acetonitrile, acetic acid, and ammonium acetate (98%) were purchased from Wako 138 
Chemicals (Osaka, Japan). Ultrapure water (Milli-Q water) was obtained using a Direct-Q3 water 139 
purification system (Millipore, Japan). Oasis HLB cartridges (30 mg, 1 mL) were purchased from 140 
Waters (Milford, MA, USA). Analytical certified solution standards of cis-tramadol hydrochloride, 141 
O-desmethyl-cis-tramadol hydrochloride, N-desmethyl-cis-tramadol hydrochloride, fluoxetine 142 
hydrochloride, and norfluoxetine oxalate, were purchased from Sigma–Aldrich (St. Louis, MO, 143 
USA). Internal standard (IS) solutions of tramadol-
13
C-d3 hydrochloride, 144 
O-desmethyl-cis-tramadol-d6 hydrochloride, fluoxetine-d6 hydrochloride, and norfluoxetine-d6 145 
oxalate, were purchased from Sigma–Aldrich (St. Louis, MO, USA). 146 
 147 
Test Fish. Adult fathead minnows (Pimephales promelas), approximately seven months old, 2.6 ± 148 
0.53 g average weight, and 5.4 ± 0.30 cm average length, were supplied from breeding stocks 149 
maintained at Brunel University London, UK. Ten days before the beginning of chemical dosing, 150 
sexually mature males were transferred into the flow-through systems for acclimation to the test 151 
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conditions. Fish were fed three times per day: once with adult brine shrimp (Tropical Marine 152 
Centre, Gamma irradiated), and twice with flake food (King British Tropical flake food), 153 
throughout the experiment. This study was carried out under Project and Personnel Licences 154 
granted by the UK Home Office, which follows the United Kingdom Animals (Scientific 155 
Procedures) Act 1986, and the European Animal Directive 2010/63/EU.  156 
 157 
Experimental Design. A preliminary short-term exposure test with two different pH conditions 158 
was performed before the chronic 23−24 days exposure test, to assess the effect of water pH on 159 
uptake of tramadol by fish. Thirty-two fish were transferred into 2 glass tanks (n = 16 in each tank) 160 
which were filled with 20 L of thermostatically-heated dechlorinated tap water adjusted to pH 8.1 ± 161 
0.09 (short-term treatment A) or 8.5 ± 0.09 (short-term treatment B) by addition of 0.1 M NaOH. 162 
Water concentrations of tramadol in tanks were nominally set at 100 µg L
-1
 by adding 4 mL of 163 
tramadol solution (500 mg L
-1
 in DMF: Milli-Q water (1:4, v/v)) to 20 L of dechlorinated tap water. 164 
Test water in tanks was partially renewed (50%) every 12 h, resulting in approximately 70% daily 165 
replacement. Four fish were sampled from each tank at 12, 24, 48, and 72 h, for analysis of 166 
tramadol in plasma.  167 
  The 23−24 days chronic exposure was carried out using a continuous flow-through system 168 
comprising twelve 20.5 L glass tanks (dimensions: 45(l) x 24(w) x 19(d) cm). The test was run at a 169 
photoperiod of 16 h light: 8 h of dark, with 20 min dawn/dusk transition periods. During the 170 
experiment, the temperature of water, pH, and dissolved oxygen concentrations were maintained at 171 
25 ± 1°C, 7.8 ± 0.19 (7.5–8.2), and 6.0–8.0 mg L
-1
, respectively. Thermostatically-heated 172 





), which supplied approximately 12 tank volumes per day to each test tank. The same 174 
mixing chambers also received stock solutions containing test chemicals delivered via peristaltic 175 
pumps at a rate of approximately 33 µL min
-1
 (2 mL h
-1
). The stock solutions containing test 176 
chemicals were prepared every four days in amber bottles with DMF: Milli-Q water (1:4, v/v) as a 177 
Page 7 of 37
ACS Paragon Plus Environment
Environmental Science & Technology
 8
carrier solvent. The final DMF concentration in the test water was approximately 0.004%. Six 178 
exposure treatment groups: water dilution control (WDC), solvent control containing 0.004% of 179 
DMF (SC), 1 µg L
-1
 (TG-1), 10 µg L
-1 
(TG-10), and 100 µg L
-1
 (TG-100) of tramadol, and 100 µg 180 
L
-1
 of fluoxetine (FG-100), were prepared. Each treatment group had two replicates (2 tanks). Eight 181 
males were randomly allocated to the glass tanks, giving a total of 16 fish per treatment. The 182 
concentrations of chemicals in the test water were chosen to cover both environmentally and 183 
pharmacologically relevant concentrations. The highest water concentration (100 µg L
-1
) was 184 
chosen in order to produce fish plasma levels of tramadol proximate to the human therapeutic 185 




. Water samples (1 mL) were collected in 186 
polypropylene tubes on day-0, 1, 2, 4, 7, 10, 14, 16, 19, and 22 from all tanks, to measure the water 187 
concentrations of test chemicals. 188 
  After the 23−24 days chemical exposure, all fish were individually anaesthetised with an 189 
aqueous solution of ethyl 3-aminobenzoate methanesulfonate (0.5 g L
-1
 of MS-222 at pH 7.5), 190 
according to UK Home Office regulations. Fish blood was taken from the caudal vein using 191 
heparinized capillary tubes. Blood samples were centrifuged (8000 × g, 5 min, 4◦C) to obtain 192 
plasma samples. The plasma samples were stored at −80°C until chemical analysis. Standard length 193 
and body weight of fish were measured, and then fish brain was collected, weighed, snap-frozen in 194 
liquid nitrogen, and stored at −80°C until subsequent analysis.  195 
 196 
Chemical analysis. Detailed information on analytical procedures for identification and 197 
quantification of tramadol and its metabolites T-M1 and T-M2, as well as fluoxetine and its 198 
metabolite norfluoxetine in water, plasma, and brain samples, can be found in the Supporting 199 
Information (SI). Briefly, 10 to 20-fold diluted water samples were directly injected in an 200 
instrument described below. Plasma samples (10 µL) were subjected to protein precipitation with 201 
IS solution, acetate buffer, and methanol. Following centrifugation, an aliquot of the supernatant 202 
was diluted with Milli-Q water. Totally 20 to 500-fold diluted plasma extracts were directly 203 
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injected in an instrument described below. Brain samples (14–25 mg) were homogenized in IS 204 
solutions, acetate buffer, methanol, and acetonitrile, subsequently subjected to protein precipitation 205 
and ultrasonically extraction. Following centrifugation, an aliquot of the supernatant was diluted 206 
with Milli-Q water. The water-diluted sample was loaded onto an Oasis HLB cartridge, the analytes 207 
retained in the cartridge were then eluted with methanol. The solvent was evaporated and the 208 
contents were reconstituted in methanol: Milli-Q water (4:6, v/v). Totally 20 to 2000-fold diluted 209 
brain extracts were injected in an instrument described below. Instrumental analysis was performed 210 
on an ultra-high-performance liquid chromatograph system (UFLC XR, Shimadzu, Japan) coupled 211 
to an AB Sciex Qtrap 5500 mass spectrometer (Applied Biosystems Sciex, Tokyo, Japan) operating 212 
in electrospray ionization (ESI) positive mode with multiple reaction monitoring (MRM).  213 
 214 
Quality Assurance and Control (QA/QC). Target compound concentrations were determined by 215 
an isotope-dilution method. IS-corrected recovery rates of target compounds in plasma and brain of 216 
fish were determined by triplicate analyses of target compound-free fish tissues spiked with target 217 
compounds at 6 concentrations ranging from 0.1 to 10000 ng mL
-1
 plasma or ng g 
-1
 brain. Method 218 
detection limits (MDLs) were calculated from the standard deviation (SD) of nine replicate 219 
injections of the fortified tissue extracts (at the lowest concentrations spiked). IS-corrected recovery 220 
rates, precision, and MDLs for plasma and brain samples are shown in Supporting Information 221 
(Table S2 and S3). IS-corrected recovery rates ranged between 85.2% and 126%, with relative 222 
standard deviations less than 15%. 223 
 224 
Prediction of Tramadol Concentration in Fish Plasma. A fish plasma model (FPM) has been 225 
proposed as a screening technique to estimate potential risk of pharmaceuticals to wild fish.
19,34,35
 226 
In the FPM, drug plasma concentration is predicted using the theoretical partition coefficient 227 
between water and fish blood based on chemical lipophilicity. The predicted fish plasma 228 
concentration is then compared with the widely available effective drug concentrations in human 229 
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plasma (human therapeutic plasma concentration ranges). However, the original fish blood−water 230 
partitioning model was developed based on empirical data for neutral organochlorine compounds 231 
such as polychlorinated biphenyls (PCBs) that are relatively stable in animal tissues.
36
 The original 232 





× 0.16) + 0.84  (1) 234 
where PBW is the equilibrium blood−water partition coefficient, Kow is the octanol−water partition 235 
coefficient. This equation was developed using empirical data from rainbow trout, and the terms of 236 
0.16 and 0.84 represent the organic (lipids and proteins) and aqueous fractions in rainbow trout 237 
whole blood, respectively. 238 
  In recent years, pH-dependent octanol−water partition coefficient (Dow) has been proposed as an 239 
alternative to Kow, to more accurately reflect partitioning for ionisable pharmaceuticals.
5,37–44
 By 240 
using Dow as a parameter, various authors have successfully predicted the plasma drug 241 






, and 242 
oxazepam
39
. On the other hand, liposome−water partition coefficient (Klipw) has been expected to 243 
be a more accurate descriptor than Kow to estimate bioconcentration of ionisable chemicals in 244 
organisms.
46–49




  In the present study, steady-state plasma bioconcentration factors (BCFplasma: fish plasma/water 247 
concentration ratios) of tramadol in fathead minnows were predicted by the concept of PBW 248 
described above, based on an assumption that the tramadol concentration in fish plasma and whole 249 
blood is approximately equal, as blood-to-plasma ratio was previously determined at 1.09 ± 0.02 in 250 
healthy male volunteers.
50
 The aqueous fraction in the whole blood of fathead minnow (87.6%) is 251 
slightly higher than that in rainbow trout (83.9%).
51
 Thus, the original equation was modified based 252 
on the difference in blood composition between rainbow trout and fathead minnow, and the 253 
following equations were obtained.  254 
BCFplasma = (10
0.73logKow 
× 0.12) + 0.88  (2) 255 
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× 0.12) + 0.88  (3) 256 
BCFplasma = (10
0.73logDlipw 
× 0.12) + 0.88  (4) 257 
The pH-dependent Dow was calculated by  258 
Dow = ƒneutral × Kow (neutral) + ƒion × Kow (ion)  (5) 259 
where fneutral and fion are the fractions of the neutral and ion species at the study pH, respectively, 260 
and Kow (neutral) and Kow (ion) are the respective Kow values. The relationship between fion and fneutral is 261 
defined by 262 
ƒion= ƒneutral × 10
|pH−pKa|  
(6) 263 
It was assumed that log Kow (ion) is 3.5 log units lower than the corresponding log Kow (neutral).
52
 Mean 264 
pH values measured in each tank were used for the calculation. Although various programs have 265 
been developed to predict log Kow, each program uses different algorithms. Given the uncertainty of 266 
calculating log Kow, we used the lowest and the highest log Kow values (2.45 and 3.01, respectively) 267 
from databases and reported pKa value of 9.41 to predict BCFplasma. Physicochemical properties of 268 
tramadol were summarized in Table S4 in the supporting information. The pH-dependent log Dlipw 269 
was calculated by  270 
Dlipw = ƒneutral × Klipw (neutral) + ƒion × Klipw (ion)  (7) 271 
where fneutral and fion are the fractions of the neutral and ion species at the study pH, respectively, 272 
and Klipw (neutral) and K lipw (ion) are the respective Klipw values. The Klipw (neutral) was calculated with the 273 
PP-LFER equation
53
 for log Klipw (neutral, 25˚C) = 0.48 + 0.55L – 0.95S – 0.05A – 4.02B + 1.65V and 274 
chemical parameters taken from the UFZ-LSER database v 3.1
54
. The Klipw (ion) was calculated with 275 
COSMOmic extended for the description of charged organic chemicals via the implementation of 276 
the membrane bilayer potential.
37,46
 Eventually, measured tramadol concentrations in plasma of 277 
fathead minnows were compared with the concentrations predicted by the BCFplasma estimated 278 
using three different chemical lipophilic parameters (Kow, Dow, and Dlipw), i.e. equations (2), (3), (4). 279 
Mean tramadol water concentration measured in each tank was used for the prediction. 280 
 281 
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Statistical Analysis. Normal distribution and homogeneity of variance were tested with 282 
Shapiro−Wilk and Levene’s tests, respectively. For data with normal distribution and variance 283 
homogeneity, parametric tests were applied. If the data did not show a normal distribution, 284 
nonparametric tests were applied. Eventually, comparing BCFplasma values between short-term 285 
treatment A and B, non-parametric Mann-Whitney-Wilcoxon rank sum tests were conducted. 286 
Non-parametric Kruskal–Wallis test followed by Steel-Dwass test were performed to compare the 287 
BCFplasma from different water pH conditions. For assessing the relationship between the 288 
concentration of tramadol in plasma and brain, nonparametric Spearman’s rank correlation 289 
coefficients were calculated. Parametric one-way ANOVA followed by a Tukey’s HSD test was 290 
conducted to compare brain/plasma tramadol concentration ratios among treatments. For assessing 291 
the relationship between plasma fluoxetine levels and norfluoxetine/fluoxetine concentration ratios, 292 
nonparametric Spearman’s rank correlation coefficients were calculated. A p-value of <0.05 was 293 
considered statistically significant. All statistical analyses were conducted using the open source 294 
statistical software R 3.3.2 GUI 1.68 Mavericks build (7288) (http://www.r-project.org/). 295 
 296 
RESULTS AND DISCUSSION  297 
Preliminary Experiment to Assess the Influence of Water pH on Fish Uptake of Tramadol. 298 
Measured concentrations of tramadol in test water were 96 ± 3.9 µg L
-1
 and 93 ± 4.4 µg L
-1
 for 299 
short-term treatment A and B, respectively. Time-course of tramadol concentrations in fish plasma 300 
are presented in Figure 1 (A). Although mean plasma concentrations in both treatment A (at pH 8.1) 301 
and B (at pH 8.5) increased with the exposure time, the data from 24 h to 72 h did not show 302 
significant changes. Assuming near steady-state condition, measured plasma data from 24, 48 and 303 
72 h were all used to calculate BCFplasma (24−72h). Comparing BCFplasma (24−72h) values between 304 
treatment A (median: 1.4, n = 12) and treatment B (median: 1.8, n = 12), a statistically significant 305 
difference was observed (p = 0.019). Even if plasma tramadol concentrations did not reach 306 
steady-state conditions, it can be speculated that BCFplasma (24–72h) values reflected the difference in 307 
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fish uptake rates between treatment A and B. For ionisable chemicals, it is well known that 308 
ionization can reduce their uptake into organisms owing to a decrease in their lipophilicity and 309 
accompanying membrane permeability. As tramadol is a weakly basic compound and has a pKa 310 
value of 9.41 (amino group), theoretically, 95% and 89% of tramadol are considered to be 311 
positively charged at pH 8.1 and 8.5, respectively. 312 
 313 
Tramadol and Fluoxetine Concentrations in Test Water for 23−24 Days exposure. None of the 314 
targeted chemicals were detected in any control (WDC and SC) samples. Tramadol was not 315 
detected in any fluoxetine-treated water samples, and fluoxetine was not detected in any 316 
tramadol-treated water samples. Tramadol water concentrations (mean ± SD, n = 18) measured 317 
throughout the experiment for TG-1, TG-10, and TG-100 treatment were 1.1 ± 0.053 µg L
-1
, 9.9 ± 318 
0.65 µg L
-1
, and 98 ± 5.2 µg L
-1
, respectively. Fluoxetine water concentration (mean ± SD, n = 18) 319 
measured throughout the experiment for the FG-100 treatment was 94 ± 8.5 µg L
-1
. Measured 320 
concentrations were all within ± 20% of the nominal values. Inter-tank variabilities were also 321 
within ± 20%. 322 
 323 
Concentrations of Tramadol and Its Metabolite in Fish Plasma After 23−24 Days Exposure. 324 
None of the targeted chemicals were detected in any control (WDC and SC) samples. Tramadol fish 325 
plasma concentrations (mean ± SD, n = 16) measured after the 23−24 days chronic exposure for 326 
TG-1, TG-10, and TG-100 treatment groups were 1.0 ± 0.32 ng mL
-1
, 5.9 ± 2.9 ng mL
-1
, and 46 ± 327 
12 ng mL
-1
, respectively. Within each treatment, the difference between the minimum and 328 
maximum plasma concentrations was up to 4-fold. Plasma tramadol concentrations of all fish 329 
exposed to waterborne tramadol at 98 µg L
-1
 were slightly below the human therapeutic plasma 330 




. Active metabolite T-M1 plasma concentrations (mean ± 331 
SD, n = 16) measured for TG-10 and TG-100 treatment groups were 0.88 ± 0.60 ng mL
-1
 and 3.8 ± 332 
0.99 ng mL
-1
, respectively. All plasma samples in TG-1 treatment group had T-M1 concentrations 333 
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below the MDL value (0.14 ng mL
-1
). Plasma T-M1 concentrations (3.8 ± 1.0 ng mL
-1
) of fish 334 
exposed to tramadol at 100 µg L
-1
 were approximately 10 times lower than effective plasma T-M1 335 
concentrations (40 ± 30 ng mL
-1
) reported in humans
55
. Inactive metabolite T-M2 plasma 336 
concentrations (mean ± SD, n = 16) measured for TG-1, TG-10, and TG-100 treatment groups were 337 
0.48 ± 0.21 ng mL
-1
, 1.2 ± 0.43 ng mL
-1
, and 7.2 ± 1.7 ng mL
-1
, respectively. 338 
 339 
Measured vs. Predicted Fish Plasma Concentrations and BCFplasma of Tramadol. Measured 340 
plasma concentrations were compared with the concentrations predicted by the FPM (Figure 1 (B)). 341 
When pH-dependent chemical lipophilicity (Dow or Dlipw) was used for the prediction, measured 342 
median values were 2–6 times lower than predicted values. When using FPM for estimating the 343 
potential risk of pharmaceuticals, an overestimated prediction would not be serious from the 344 
viewpoint of precautionary principle. Nevertheless, the disagreement between measured and 345 
predicted plasma tramadol concentrations in fathead minnows might be due to differences in the 346 
existence form in the blood and/or hepatic clearances, between tramadol and PCBs. In fact, plasma 347 
protein binding of tramadol in human was reported to be approximately 20%
56
, while lipid-soluble 348 
PCBs can be highly retained in the blood lipids. For the clearance of tramadol, we found its 349 
metabolites T-M1 and T-M2, with the concentration ratios of tramadol: T-M1 + T-M2 = 4:1 in 350 
plasma of fathead minnows. As it can be presumed that biotransformation of tramadol in fish 351 
occurs much faster than PCBs, metabolism of tramadol by fathead minnow is likely involved in the 352 
disagreement between measured and predicted plasma tramadol concentrations. Accounting for the 353 
protein binding and metabolism, BCFplasma of tramadol can be predicted by 354 
BCFplasma = [(10
0.73logα 
× 0.12 × ƒbp) + 0.88] ×ƒparent (8) 355 
where α is Dow or Dlipw, the terms of 0.12 and 0.88 represent the organic and aqueous fractions in 356 
fathead minnow whole blood, respectively, and ƒbp is the fraction bound to proteins (value 357 
measured in human plasma: 0.20), ƒparent is the fraction of parent compound tramadol 358 
(tramadol/tramadol + TM-1 + TM-2 concentration ratio in plasma of fathead minnow: 0.80). When 359 
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comparing measured tramadol concentrations in plasma of fathead minnow with the concentrations 360 
predicted by the BCFplasma estimated using the equation (8), only 0.86−1.8 fold differences were 361 
observed. In the present study, only 2 metabolites (i.e., TM-1 and TM-2) in fathead minnow were 362 
measured and the ƒparent of 0.80 was applied as a provisional value. The actual value should be 363 
lower than 0.80, because 23 metabolites of tramadol were previously identified in human urine.
57
 364 
Additionally, several study have reported that 25–30% of an oral dose is excreted as unchanged 365 
drug in the urine of human, whereas 55–60% of an oral dose is excreted as metabolites.
56
  366 
  Measured BCFplasma of tramadol for 23−24 days exposure are shown in Figure 1 (C). These 367 
BCFplasma values, ranging from 0.29 to 1.6 for fathead minnows, were similar to or slightly lower 368 
than those for rainbow trout (min–max: 2.3–3.3) exposed to treated wastewater in Sweden
58
. 369 
Measured BCFplasma values were the highest for TG-1 treatment group, followed by TG-10 and 370 
TG-100 treatment groups. Combining results from preliminary short-term and 23−24 days chronic 371 
experiments, it was found that BCFplasma values increased as the water pH increased (Figure 1 (D)). 372 
The lowest (median BCFplasma: 0.44) and the highest (median BCFplasma: 1.8) values were found at 373 
pH 7.6 and 8.5, respectively. Theoretically, 99% and 89% of tramadol are considered to be 374 
positively charged at pH 7.6 and 8.5, respectively. Our result supports previous studies
5,38,42,59–61
, 375 
highlighting the importance of taking the water pH influence into account when BCFplasma of 376 
ionisable chemicals are estimated. From the viewpoint of environmental risk assessment for basic 377 
chemicals, using water-based threshold values from in vivo tests at only neutral water pH can lead 378 
to underestimation of their actual risks in natural alkaline surface waters, as pointed out by Boström 379 
et al. (2015)
62
.  380 
 381 
Tramadol and Its Metabolite Concentrations in Fish Brain After 23−24 Days Exposure. None 382 
of the targeted chemicals were detected in any control (WDC and SC) samples. Tramadol brain 383 
concentrations (mean ± SD, n = 16) measured after the 23−24 days exposure for TG-1, TG-10, and 384 
TG-100 treatment groups were 4.6 ± 1.4 ng g
-1
, 26 ± 10 ng g
-1
, and 200 ± 49 ng g
-1
, respectively. 385 
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T-M1 brain concentrations (mean ± SD, n = 16) measured for TG-1, TG-10, and TG-100 treatment 386 
groups were below the MDL value (0.56 ng g
-1
), 1.4 ± 0.40 ng g
-1
, and 11 ± 3.5 ng g
-1
, respectively. 387 
T-M2 brain concentrations (mean ± SD, n = 16) measured for TG-1, TG-10, and TG-100 treatment 388 
groups were 0.73 ± 0.17 ng g
-1
, 2.6 ± 0.75 ng g
-1
, and 24 ± 7.8 ng g
-1
, respectively. Recent results 389 
from an in vitro human blood-brain barrier model and an in vivo rodent study have shown that 390 
tramadol is actively transported from blood to brain by a proton–coupled organic cation antiporter 391 
located in the blood–brain barrier.
63
 When examining a relationship between brain and plasma 392 
individual concentrations for tramadol, T-M1, and T-M2 (Figure 2 (A)), strong positive correlations 393 
were shown for all these chemicals (r = 0.83–0.97, p < 0.001). Brain/plasma tramadol concentration 394 
ratios were consistent among treatments (Figure 2 (B)) (p = 0.86), showing a dose-independent 395 
manner. These concentration ratios (min–max: 2.2–7.5) were similar to those reported for rodents 396 
(min–max: 1.3–7.3)
64–66
. The similarity in brain/plasma tramadol concentration ratios between fish 397 
and rodents supports the species-extrapolation and predictive pharmacology/toxicology 398 
approaches
13
. On the other hand, dose-dependent increases in brain/plasma concentration ratios 399 
were observed for both T-M1 (p = 0.010) and T-M2 (p = 0.0001). The reason is unclear, but 400 
metabolism of tramadol into T-M1 and T-M2 might be induced in the brain of higher dose groups 401 
due to higher tramadol concentrations in the brain. As another possible reason, the protein-unbound 402 
(free) T-M1 and T-M2 in plasma, which can penetrate the blood-brain barrier, might increase by the 403 
reduction of plasma protein binding sites available for these metabolites because of the increase in 404 
plasma tramadol concentrations. However, our fish plasma concentration data represents the total 405 
(both protein-bound and unbound) tramadol levels. Measurement of free tramadol, T-M1, and T-M2 406 
in fish plasma will be needed to verify whether or not high dose of tramadol can increase amount of 407 
free T-M1 and T-M2. Interestingly, brain/plasma T-M1 concentration ratios (min–max: 0.59–5.9) 408 
were greater than those reported for rodents (min–max: 0.23–1.3)
64,65
.  409 
 410 
A Comparison of Fish Metabolic Data with Mammalian Data. A comparison of 411 
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metabolites/tramadol concentration ratios in plasma of fish with literature values reported in plasma 412 
of various species including human beings, rodents, cats, and dogs is shown in Table S5 413 
(Supporting Information) and Figure 3 (A). T-M1/tramadol concentration ratios, which were 0.087 414 
± 0.028 (mean ± SD, n = 16) in plasma of fish exposed to 98 µg L
-1
 of tramadol, were 2–6 times 415 
lower than literature values (0.17–0.52) reported in general humans
67–70
. Meanwhile, the 416 
T-M2/tramadol concentration ratio, which was 0.16 ± 0.031 (mean ± SD, n = 16) in plasma of fish 417 
exposed to 98 µg L
-1
 of tramadol, was quite similar to literature values (0.074–0.14) reported in 418 
humans
68–70
. Interestingly, T-M1/tramadol concentration ratios measured in fish are comparable to 419 
those previously reported in a human who was classified as a CYP 2D6 poor metabolizer
67
. 420 
Although fathead minnows are able to metabolize tramadol as humans do, the apparently slower 421 
metabolism of tramadol into the active metabolite T-M1 indicates that this species of fish is less 422 
capable of metabolising tramadol into T-M1 than most humans; this might result in decreased 423 
analgesic efficacy of the drug. A recent publication
71
 has shown that T-M2 levels greater than T-M1 424 
levels were present in the brain of zebrafish (Danio rerio) after administration of a single 425 
intramuscular dose of tramadol, supporting the results of our study, although that paper is not 426 
concerned with the environmental impact of pharmaceuticals, nor the relevance of drug metabolism 427 
to any potential impact. As shown in Table S5 and Figure 3 (A), the metabolites/tramadol 428 
concentration ratios are significantly variable among animal species; differences in the 429 
T-M1/tramadol concentration ratio occur not only between fish and humans, but also between 430 
different mammalian species. In rodents, high metabolic rates of tramadol into T-M1 compared 431 
with those in humans have been reported,
65
 whereas in dogs, horses, and donkeys, T-M1 seemed to 432 
be a relatively minor metabolite.
72–74
 These animals produce less T-M1 and more T-M2, as fathead 433 
minnows do. Differences in metabolism of tramadol between different aquatic organisms as well as 434 
fish species can be a question of future interest. 435 
  A comparison of norfluoxetine (N-desmethyl fluoxetine)/fluoxetine concentration ratios in 436 
plasma of fish with literature values reported in plasma of fish, rodents, and human beings is shown 437 
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in Table S6 (Supporting Information) and Figure 3 (B). In our previous study
40
, in which fathead 438 
minnows were exposed to fluoxetine at water concentrations ranging from 0.1 to 64 µg L
-1
, we 439 
found a change in the slope of the linear regression between water and fish plasma concentrations 440 
when water concentrations exceeded 16 µg L
-1
. This variation in slope occurred simultaneously 441 
with the decrease of norfluoxetine/fluoxetine concentration ratios. Those results were also 442 
confirmed in the present study (Figure S1, Supporting Information), and are likely due to the 443 
saturation and/or inhibition of the enzymatic system involved in fluoxetine metabolism. Such a 444 
process has also been well documented in both humans and rodents at similar plasma 445 
concentrations.
32,75–78
 In clinical studies and in vivo rodent studies, norfluoxetine/fluoxetine 446 





, showing that concentrations of circulating fluoxetine and norfluoxetine are mostly in 448 
the same range
75–77,79
. On the other hand, norfluoxetine/fluoxetine concentration ratios for fathead 449 
minnows were 3.0 ± 1.1 when plasma fluoxetine levels were 390 ± 240 ng mL
-1
. Nakamura and 450 
coworkers
41
 previously observed norfluoxetine/fluoxetine ratios between 2.2 and 8.5 for Japanese 451 
medaka (Oryzias latipes) exposed to fluoxetine at 14–15 µg L
-1
 water for 30 days at water pH of 452 
7–9. From these results, it is possible to hypothesise that fish are able to transform fluoxetine into 453 
norfluoxetine more efficiently than humans do, as suggested by the higher norfluoxetine/fluoxetine 454 
ratios. 455 
  In humans, tramadol primarily undergoes CYP 2D6-catalyzed O-demethylation to the active 456 
metabolite T-M1, and CYP 2B6 and 3A4-catalyzed N-demethylation to inactive metabolite T-M2. 457 
T-M1 and T-M2 are further metabolized to the following metabolites: N, N-didesmethyl tramadol, 458 
N, N, O-tridesmethyl tramadol, and N, O-desmethyl tramadol. All these metabolites are finally 459 
conjugated with glucuronic acid and sulfate to be excreted by the kidneys.
30
 In the case of 460 
fluoxetine, CYP 2D6, 2C9, 2C19, and 3A4 are responsible for N-demethylation of fluoxetine in 461 
humans; beside, fluoxetine undergoes direct conjugation with glucuronic acid.
32,78,80
 Due to an 462 
apparent deficiency of 2B, 2C, and 2D homologues of CYPs in fish, it is plausible to hypothesise 463 
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that other fish-specific CYP 2 subfamilies (e.g., CYP 2K and 2Y) are involved in the metabolism of 464 
tramadol and fluoxetine in fish. It is also important to consider that 47 CYP2 genes were identified 465 
in zebrafish, in contrast to 16 in humans.
31
 The quantitative functional properties of those isoforms 466 
remain largely unknown; nonetheless, their characterization remains an important research task for 467 
the future, as this information would dramatically increase the accuracy and predictive power of 468 
pharmacokinetic models for fish species. So far, one possible interpretation of the metabolite/parent 469 
concentration ratios obtained for tramadol in the present study is that CYP 2 subfamilies-catalyzed 470 
O-demethylation occurs slower than CYP 3 subfamilies-catalyzed N-demethylation in fish. 471 
  The comparison of metabolite/parent concentration ratios in different animals requires a note of 472 
caution because of differences in induction/inhibition/saturation dynamics of metabolic enzymes. 473 
Additionally, the results discussed here were obtained using fish exposed to the drug via water. This 474 
type of administration route results in sustained levels of the drug in the blood for the duration of 475 
the experiment, as drug uptake via the gills is continuous. This exposure scenario is to some extent 476 
different than drug administration in humans and other mammal species, which typically occur with 477 
lower intra-day frequency, resulting in plasma concentrations that display more pronounced 478 
oscillatory dynamics than in fish. At this stage, we do not know the exact quantitative implications 479 
of these different exposure dynamics on the metabolic capabilities between fish and mammal 480 
species.  481 
  Tramadol is a pro-drug that requires metabolic activation to become a pharmacologically active 482 
molecule (i.e., µ-opioid receptor agonist). Unless fish are able to metabolise the parent tramadol 483 
into T-M1, the opioid receptor-mediated effects (e.g., sedative and analgesic effects) on fish would 484 
not be observed. Considering the fact that approximately 10% of all approved small molecular 485 
drugs on the global market are classified as pro-drugs,
81
 it is scientifically worthwhile for the 486 
environmental risk assessment to understand drug metabolism in aquatic organisms such as fish. In 487 
addition, it is meaningful to measure the concentrations of these active metabolites as well as 488 
parent inactive substances in the environment. So far, only limited data are available on the 489 
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occurrence and fate of active metabolites in the aquatic environment. There is, for example, a small 490 
amount of data on tramadol, which reported T-M1/tramadol concentration ratios ranging from 0.1 491 
to 2.9 in WWTP effluents in Germany.
21
 492 
  In conclusion, the main finding of this study is that the teleost fish fathead minnow metabolises 493 
tramadol in a similar manner to humans and other mammalian species, and that concentration ratios 494 
of T-M1 to tramadol observed in the fish were comparable to the lower range of values previously 495 
reported in humans, and much lower than the values previously found in mouse, rat, and cat, which 496 
may be highly relevant when attempting to predict the environmental risk of this compound. The 497 
presence of T-M1 in fish suggest that the opioid receptor-mediated effects (e.g., sedative and 498 
analgesic effects) of tramadol would occur in fish once internal T-M1 concentrations are high 499 
enough to produce these effects. It is therefore likely that other opioids administered as pro-drugs, 500 
such as codeine and oxycodone, will be effective in fish, because in humans both have to be 501 
activated (O-demethylated) into their active metabolites morphine and oxymorphine, respectively. 502 
The amount of information available so far on drug metabolism in fish, although limited, supports 503 
the contention that fish metabolise human pharmaceuticals in the same way as humans and other 504 
mammalian species do. For example, the cardiovascular drug clofibric acid is metabolised by 505 
zebrafish embryos to at least 18 metabolites,
82
 the calcium channel blocker diltiazem is metabolised 506 
to at least 8 metabolites,
83
 and the anti-epileptic carbamazepine is metabolised to two or more 507 
metabolites,
10
 all of which have been identified in mammals administered these drugs. We are 508 
aware of only two studies to date in which metabolism of a pro-drug by fish has been studied. Both 509 
studies
84,85
 showed that the glucocorticoid pro-drug beclomethasone dipropionate is readily 510 
metabolised by fish to the active moieties beclomethasone 17-monopropionate and beclomethasone, 511 
just as it is in humans and other mammalian species. Thus, if no evidence of the metabolism of a 512 
pro-drug is available to utilise in an environmental risk assessment, it seems reasonable to assume 513 
that fish will metabolise the pro-drug to the same active metabolites produced in mammals, as a 514 
worst-case assumption. This realisation strengthens the arguments for utilizing the read-across 515 
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 in the environmental risk assessment of pharmaceuticals.  516 
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 822 
Figure 1. Plasma concentrations and BCFplasma (fish plasma/water concentration ratios) of 823 
tramadol in the fathead minnow. (A) Time-course of tramadol concentrations (mean ± SD, n = 4) 824 
in plasma of fish exposed to 100 µg L
-1
 of tramadol at water pH 8.1 (short-term treatment A) or 8.5 825 
(short-term treatment B). Different letters above error bars denote significant differences between 826 
time periods (p < 0.05, one-way ANOVA followed by a post hoc Tukey HSD test). (B) Measured 827 
(red dashed line, median, n = 16; black dots, individuals) and predicted (dot-dot-dashed line and 828 
dot-dashed line) plasma concentrations of tramadol after 23−24 days exposure. The grey 829 
dot-dot-dashed line and dot-dashed line were calculated by using the highest and the lowest log Kow, 830 
respectively; the yellow dot-dashed line was calculated by using the log Dlipw; the blue 831 
dot-dot-dashed line and dot-dashed line were calculated by using the highest and the lowest log Dow, 832 
respectively (Table S4).  The grey area indicates the human therapeutic plasma concentration 833 
(HTPC) range (100–300 ng mL
-1
). (C) BCFplasma values of tramadol at water concentrations of 1 834 
(TG-1), 10 (TG-10), and 100 (TG-100) µg L
-1
. The box plots show 5th (lower whisker), 25th 835 
(bottom edge of box), 75th (top edge of box), and 95th (upper whisker) percentiles. The horizontal 836 
line in the box represents the median value. The small dots (○) are outliers. (D) pH-dependent 837 
measured (red dashed line, median; black dots, individuals) and predicted (dot-dot-dashed line and 838 
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dot-dashed line) BCFplasma of tramadol after 23−24 days or 24–72-h exposure test. The yellow 839 
dot-dashed line was calculated by using the log Dlipw; the blue dot-dot-dashed line and dot-dashed 840 
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 865 
Figure 2. Brain concentrations and brain/plasma concentration ratios of tramadol and its 866 
metabolites in the fathead minnow. (A) The relationship (Spearman's rank correlation coefficient) 867 
between brain and plasma individual fish concentrations of tramadol, T-M1, and T-M2. Y-axis: 868 
chemical concentrations in the brain, X-axis: chemical concentrations in the plasma. The dashed 869 
line represents an exact match between chemical levels in plasma and brain. (B) Brain/plasma 870 
concentration ratios of tramadol, T-M1, and T-M2 at water concentrations of 1 (TG-1), 10 (TG-10), 871 
and 100 (TG-100) µg L
-1
. The box plots show 5th (lower whisker), 25th (bottom edge of box), 75th 872 
(top edge of box), and 95th (upper whisker) percentiles. The horizontal line in the box represents 873 
median value. The small dots (○) are outliers. The ratios of T-M1 at water concentrations of 1 µg 874 
L
-1 
(TG-1) are not shown due to non-detectable concentrations in both plasma and brain. 875 
 876 
 877 
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 878 
Figure 3. Inter-species differences in drug metabolism. (A) O-desmethyl tramadol/tramadol 879 
concentration ratios in plasma of mouse, rat, cat, human, dog, and fish. Fish values were calculated 880 
by dividing individual plasma concentrations of O-desmethyl tramadol by individual plasma 881 
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concentrations of tramadol in the present study. Mammalian values were estimated by dividing the 882 
mean plasma concentration of O-desmethyl tramadol by the mean plasma concentration of 883 
tramadol in the literature mentioned in Table S5 (Supporting Information). (B) Norfluoxetine 884 
(N-desmethyl fluoxetine)/fluoxetine concentration ratios in plasma of fish, rat, and human. Fish 885 
values were calculated by dividing individual plasma concentrations of norfluoxetine by individual 886 
plasma concentrations of fluoxetine in the present study. Mammalian values were estimated by 887 
dividing the mean plasma concentration of norfluoxetine by the mean plasma concentration of 888 
fluoxetine in the literature mentioned in Table S6 (Supporting Information). 889 
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